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Background: The objective of this study was to compare the efficacy and safety of taxane (docetaxel or paclitaxel),
cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil (PF) regimen by a meta-analysis of data retrieved
from the literature.
Methods: Seven randomized clinical trials were identified, which included patients with advanced head and neck
cancer who underwent induction chemotherapy with either a Tax-PF or PF protocol. The outcomes included the
3-year and 5-year overall survival (OS) and progression-free survival (PFS), overall response rate (ORR) and different
types of adverse events.
Results: The 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P = 0.008), 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43;
P = 0.002), 5-year OS rate (HR: 1.30; 95% CI, 1.09 to 1.55;P = 0.003), 5-year PFS rate (HR: 1.39; 95% CI, 1.14 to 1.70;
P = 0.001) and ORR to chemotherapy (OR 1.66; 95% CI, 1.35 to 2.05; P < 0.001) of the patients in the Tax-PF group
were statistically superior to those in the PF group. In terms of toxicities, the incidence of febrile neutropenia
(OR 2.36; 95% CI, 1.62 to 3.46; P < 0.001), alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P < 0.001), diarrhea (OR 1.57; 95%
CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P < 0.001) was higher in the Tax-PF group.
Conclusion: The Tax-PF induction chemotherapy improved PFS and OS, and the ORR was better as compared to
PF-based therapy regimens at the cost of a higher incidence of adverse events.
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Head and neck squamous cell carcinoma is one of
commonest malignant tumors, frequently diagnosed
in an unresectable advanced stage (Siegel et al. 2014).
A meta-analysis on chemotherapy in head and neck
cancer (MACH-NC) has demonstrated that concomitant
chemoradio-therapy using traditional cisplatin and
fluorouracil (PF) regimen improved the survival in patients
with distant metastases and should be regarded as the
principal treatment (Pignon et al. 2009). Nevertheless,* Correspondence: andreas.albers@charite.de
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in any medium, provided the original work is pinvestigators are continuously evaluating new regimens in
the induction setting to improve ORR, PFS and OS.
Among agents introduced in the 1990s, taxanes have
shown great promise for the treatment of head and
neck squamous cell carcinoma (HNSCC) (Schrijvers
and Vermorken 2000). The clinical efficacy of induction
chemotherapy using a PF regimen doubled while a
three-drug combination of taxane (docetaxel or paclitaxel),
cisplatin, and fluorouracil (Tax-PF) is still undergoing
evaluation in several randomized controlled trials (RCTs)
with varying results (Blanchard et al. 2013; Forastiere et al.
2013; Tural and Kilickap 2014).
This meta-analysis was conducted to review all eligible
RCTs comparing combined therapy with or without
taxanes, with the aim of investigating whether Tax-PFOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and neck cancer while adverse effects are still tolerable.
Materials and methods
Literature search
PubMed, Embase, SpringerLink, MEDLINE, the Cochrane
Library and the American Society of Clinical Oncology
(ASCO) Annual Meeting and ASCO virtual meeting data-
bases were searched for entries until June 2014, using the
following search keywords: “randomized”, “head and neck
cancer” , “HNSCC” , “induction chemotherapy” and “taxanes
or docetaxel or paclitaxel”. Articles and general reviews of
this topic were examined and excluded manually.
Study selection
Clinical trials that fulfilled the following criteria were
included in the study: (1) prospective RCT; (2) originalFigure 1 Flow-chart for identification of eligible studies.articles that include a censored number of patients or
Kaplan–Meier-curves; (3) studies that analyzed combined
therapy regimen with taxanes versus without taxanes;
(4) comparisons of combined Tax-PF induction chemother-
apy to regimen with traditional PF double-chemotherapy
(Figure 1).
To limit publication bias, only published data were
included. Studies containing one of the following criteria
(1) phase I clinical trial; (2) retrospective trial; (3) any
review, comment, and case report were excluded from
the analysis.
Data extraction and study quality
Studies were extracted from the databases by two of the
authors separately. Next, between the authors a consensus
was achieved that the data from the chosen publications
met the inclusion criteria. Then the following information
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did not contain all of the following information: first au-
thor, publication year, country of patient’s origin, treatment
regimen, patient number, age, gender, treatment line,
ECOG (Eastern Cooperative Oncology Group) perform-
ance status (PS) or WHO status or Karnofsky status (KPS),
median overall survival (OS), progression-free survival
(PFS), overall response rate (ORR), adverse events (AEs),
specific grade 3–4 toxicity data and general symptoms
(alopecia, infection, and asthenia), hematological system
syndrome (neutropenia, thrombocytopenia, and anemia),
digestive system syndrome (nausea/vomiting, diarrhea, and
anorexia), and neuropathy. In studies where the log hazard
ratio (HR) and its variance was not explicitly presented the
method described by Parmar et al. was applied to extract
estimates of these statistics (Parmar et al. 1998). In those
instances where studies contained overlapping sets of
patients, the longest follow-up or the largest number of
events was selected. The methodological quality of the
reports integrated in this meta-analysis was evaluated
using the Jadad composite scale (Jadad et al. 1996;
Moher et al. 1998). A general quality score was applied to
each study as follows: 0 (non-randomized controlled trials),
1, 2 (low quality studies), 3, 5 (high quality studies).
Statistical analysis
The outcomes relevant for this meta-analysis were PFS,
OS, ORR and toxicity. PFS was defined by the period from
random assignment to the first documented disease
progression. OS was defined by the period from random
assignment to death from any cause, censoring patients
who had not died at the date last known alive. ORR was
defined as the sum of partial and complete response rates
(according to the Response Evaluation Criteria in Solid
Tumors (RECIST) (Therasse et al. 2000). Toxicity was
graded according to the Common Toxicity Criteria
version 2 (http://ctep.cancer.gov). The overall HRs for OS
and PFS, the odds ratios (ORs) for ORR and AEs were
calculated using statistical software (Stata version 13.0).
Efficacy analysis was based on the intent-to-treat popula-
tion, which was defined as all randomly assigned patients.
All patients who received at least one dose of the study
drug were included in safety analysis. A p-value less than
0.05 was considered significant. An HR > 1 reflects a favor-
able outcome in the Tax-PF arm for response rate while
an OR > 1 indicates better overall response rates or higher
toxicity in the Tax-PF arm. Both the fixed-effects model
and the random-effects model was used to calculate the
pooled estimates of efficacy. The quantification of the
heterogeneity was calculated by the Cochrane Q statistic
and the I2 value. The assumption of homogeneity was
deemed invalid, when a p-value was < 0.1. Then the
random-effects models were used after exploring the
causes of heterogeneity. Otherwise, the fixed-effectsmodels were used. The results of this meta-analysis were
presented by forest plots. The individual squares represent
each study’s HR or OR estimate while the lines extending
from the squares represent the 95% confidence interval
(CI) for the estimate. The size of the square repre-
sents the weight that the corresponding study exerts
in the meta-analysis. In addition, the funnel plot, in
which the standard error of log (OR) of each study
was plotted against its log (OR) and Begg’s and the
Egger’s linear regression test were used to estimate
the publication bias. The significance of the intercept was
displayed using the t-test suggested by Begg (p < 0.05 was
considered as statistically significant) (Egger et al. 1997)
(see Additional file 1: Figure S1).
Results
Description of included trials
A total of 1098 potentially relevant papers or abstracts
were initially retrieved from the databases, of which
1091 could be excluded after thorough screening. A flow
chart summarizing search results and exclusion strategy is
provided in Figure 1. Finally, seven clinical trials were
selected for the meta-analysis (Hitt et al. 2005; Posner et al.
2007; Vermorken et al. 2007; Pointreau et al. 2009;
Vermorken et al. 2011; Lorch et al. 2011; Hitt et al.
2014).The main characteristics and detailed induction
chemotherapy regimens are summarized in Table 1.
Three-year efficacy rate
Four trials (Posner et al. 2007; Vermorken et al. 2007;
Pointreau et al. 2009; Hitt et al. 2014) provided data
regarding the 3-year PFS rate. When combined, the data
from the four trials yielded an estimated common HR of
1.24 (95% CI: 1.08 to 1.43). A significantly positive effect
on survival was found for the use of Tax-PF for induction
chemotherapy (P =0.002). Five trials (Hitt et al. 2005;
Posner et al. 2007; Vermorken et al. 2007; Pointreau et al.
2009; Hitt et al. 2014) provided data on the 3-year OR rate.
Patients treated with the Tax-PF regimen had a signifi-
cantly longer 3-year OR rate (HR: 1.14; 95% CI: 1.03 to
1.25; P = 0.008). However, a between-trial-heterogeneity
was observed for the OS analysis with an I2 value of 57.2%
(P = 0.053), but not in PFS (P = 0.545). This heterogeneity
was mainly related to the Spanish Head and Neck Cancer
Cooperative Group (TTCC) in 2014 (Hitt et al. 2014).
After eliminating this study, a reduction in the hazard of
progression for Tax-PF group (HR 1.19, 95% CI 1.07 to
1.32, heterogeneity P = 0.132, I2 = 46.5%) was found. The
main study results are detailed in Figure 2.
Five-year efficacy rate
Of the four eligible studies, 2 trials (Vermorken et al. 2011;
Lorch et al. 2011) were a long-term update to previous
trials. From these studies, we could extract data to calculate
Table 1 Characteristics of randomized controlled clinical trials in the meta-analysis
First
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Figure 2 Clinical outcome after three 3 and 5 years.
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induction chemotherapy improved the PFS rate when
compared with PF induction chemotherapy, with an
HR of death of 1.39 (95% CI, 1.14 to 1.70; P = 0.001;
Figure 2). Tax-PF induction chemotherapy also im-
proved the OS rate, with an HR of 1.30 (95% CI, 1.09
to 1.55; P = 0.003). The test for heterogeneity of the data
yielded a p-value > 0.1 (PFS: 0.387 and OS: 0.429); thus,
we accepted the hypothesis of homogeneity.
Overall response rate
The data of five trials (Hitt et al. 2005; Posner et al. 2007;
Vermorken et al. 2007; Pointreau et al. 2009; Hitt et al.
2014) were included to determine the overall response
(WHO criteria) to chemotherapy. Patients treated with
Tax-PF had a significantly higher ORR (OR 1.66; 95% CI,
1.35 to 2.05; P < 0.001). No significant heterogeneity
was found among studies used for analysis (heterogeneity
P = 0.162, I2 = 38.8%).Figure 3 Toxicity profile of Tax-PF and PF regimen.Toxicity
Data to analyse adverse events could be extracted
from seven trials. The results are presented in Figure 3.
Patients treated with the Tax-PF regimen had a sig-
nificantly higher occurrence of grade 3 to 4 febrile
neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P < 0.001),
alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P < 0.001),
diarrhea (OR 1.57; 95% CI, 1.05 to 2.36; P = 0.03) and
leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P < 0.001).
Heterogeneity was found for some adverse events, which
may be attributed to patient characteristics and to the use
of different agents at various dosages in the studies.Publication bias
Egger’s test was performed to determine the publication
bias of the literature. The results of Egger’s test did
not suggest any evidence of publication bias (P = 0.854)
(see Additional file 1: Figure S1).
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Taxanes are a group of anticancer drugs that function by
disruption of microtubule assembly and -function and
can effectively block the cell cycle in G2/M phase which
results in a mitotic arrest (Schrijvers and Vermorken
2000). In vitro studies suggested that taxanes also may
play a role in radiation sensitization (Cui et al. 2014).
Since the 1990s, taxanes have been evaluated for their
potential to treat HNSCC (Qin et al. 2012).
The MACH-NC Collaborative Group performed an
individual patient data meta-analysis with an inclusion
of 1772 patients that were recruited between 1998 and
2007. Patients treated with Tax-PF had the benefit of a
higher rate of loco-regional control (HR, 0.79; 95% CI,
0.66–0.97; P = 0.007), suffered from distant failures less
frequently (HR, 0.63; 95% CI, 0.45–0.89; p = 0.009) and
showed an absolute decrease in mortality at 5 years of
9.3% (PF vs TPF: 60.1% vs 50.8%). Nevertheless, the
trials displayed heterogeneity regarding criteria such
as patient inclusion, patient characteristics, drug regimens,
tumor site, treatment intent, primary endpoint, and espe-
cially, definitive local treatment (Forastiere et al. 2013).
The individual trial results also diminished the importance
of the meta-analysis (Mak and Glisson 2014). The out-
come of induction chemotherapy with a three-drug-
combination consisting Tax-PF for locally advanced head
and neck cancer is still a subject of debate and will remain
so for the near future.
This meta-analysis evaluated not only the 3-year efficacy
and safety, but also demonstrated for the first time a
significant improvement in 5-year efficacy and safety of
Tax-PF from two clinical studies. The long-term results
from the other three trials (Hitt et al. 2014; Hitt et al.
2005; Pointreau et al. 2009) are not available at present.
Therefore, we conclude at this point in time that the
induction chemotherapy regimen using Tax-PF is superior
to the PF regimen in terms of efficacy according to the
currently available data. However, the long-term results of
the currently ongoing trials should be included whenever
available to increase the validity of this statement.
With regards to toxicities, the Tax-PF regimen led to a
higher rate of grade 3 to 4 febrile neutropenia, alopecia,
diarrhea and leucopenia as it has been shown in this
meta-analysis (Figure 3). No difference was seen in
toxicity-related mortality, implying that there was no
increase in treatment-related deaths with Tax-PF
treatment as compared with PF-regimen alone. The
incidences of lethargy, infection, nausea and vomiting,
peripheral neuropathy, renal function and anemia were
not significantly different.
Severe adverse effects seemed predictable and manage-
able. Taking into account the toxicity-profile of Tax-PF-
induction chemotherapy on one hand and the improved
PFS and OS on the other future studies should aim toidentify characteristics of treated patients that will help to
determine the risk and benefit of distinct groups. One
currently proposed strategy is a stratification of trial-results
based on the distinct etiologies of HNSCC in future
research since human papillomavirus (HPV)- and tobacco-
related HNSCC exist (Qian et al. 2014; Qian et al. 2013).
Fakhry et al. observed the HPV status of oropharyngeal
HNSCC in a prospective clinical trial and confirmed, that
tumor HPV status is strongly associated with therapeutic
response and survival (Fakhry et al. 2008). Patients with
HPV-positive tumors displayed higher response rates to
induction chemotherapy including intravenous paclitaxel
(82% vs 55%, P = 0.01) and after chemoradiation treatment
(84% vs 57%, P = 0.007) than those with HPV-negative
tumors. After a median follow-up of 39.1 months,
compared with patients with HPV-negative tumors,
patients with HPV-positive tumors demonstrated a
significant improved OS (2-year OS = 95% vs 62%,
difference = 33%, 95% CI = 18.6% to 47.4%, P = 0.005,
log-rank test). Consequently, de-escalation treatment
protocols of HPV-associated HNSCC were developed
(Masterson et al. 2014). However, it will be necessary and
of clinical interest to identify further the underlying
mechanisms that determine a response to induction
chemotherapy in patients with HPV-associated HNSCC
and non-HPV-associated HNSCC to facilitate a proper
selection of patients that are most likely to benefit from
this therapy and thereby justifying the relatively high risk
of therapy-induced toxicity. These approaches may
include reverse bedside-to-bench research to stratify
the influence of patient’ habits and biological factors
on therapeutic outcome.
As stated by Forastiere et al. and others the ideal
sequence of chemotherapy, radiation, and surgery for
the management of loco-regionally advanced HNSCC
has not been finally defined yet (Forastiere et al. 2013;
Argiris et al. 2008).
Although non-surgical standard treatment of locally
advanced HNSCC is concurrent chemoradio-therapy
(Pignon et al. 2009; Petrelli et al. 2014; Masterson et al.
2014), there is emerging evidence, being now further
consolidated and explored, that treatment with a three-
drug regimen such as Tax-PF followed by surgery and
consolidation chemoradio-therapy of patients with recur-
rent advanced HNSCC improved the response rates and
survival (Yang et al. 2014). Other groups also reported that
induction chemotherapy tended to improve clinical
outcome with manageable toxicity (Won et al. 2014). Also
the choice of the chemotherapeutic agent in a non-
induction setting is not without controversy. While some
authors view platinum-based chemoradio-therapy as
the treatment of choice for locally advanced HNSCC
(Petrelli et al. 2014; Masterson et al. 2014) and superior to
radiotherapy combined with cetuximab, which should
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platinum-based agents is contraindicated, others recently
argued that an improved OS and reduced toxicity sup-
ports the choice of taxane-based regimens in a concurrent
setting over platinum non-taxane containing regimen
(Behera et al. 2014). However, the findings also indicated
that a better standardization of a taxane-based regimen is
needed (Behera et al. 2014).
Some shortcomings of this analysis should be taken
into account: First, like every meta-analysis, the quality
of the results is limited by the quality of the included trials.
Second, treatments were involved in a few trials based on
the different dosages. Third, only seven RCTs were
included and not all articles contained data of OS, PFS,
ORR, and some adverse effects. Fourth, although publica-
tion bias was not found, the influence of the omission of
further ongoing or yet unpublished studies cannot be in-
cluded at the time of the preparation of this manuscript.
However more long-term evidence from randomized stud-
ies is needed to further validate the therapeutic efficacy of
Tax-PF. Finally, heterogeneity of the data exists in some
outcomes in this meta-analysis, for which differences in
patient populations, concurrent chemoradio-therapies,
lengths of treatment and tumor performance status across
the included trials may be responsible.
In conclusion, our data demonstrate that the Tax-PF
induction chemotherapy regimens lead to a significant
survival advantage at the cost of an increased rate of
toxicity-related adverse effects as compared to the PF
regimen. Therefore, before administration of Tax-PF
induction chemotherapy regimen, followed by radiotherapy
or concurrent chemoradio-therapy, a careful selection of
patients seems advisable to reduce the incidence and
severity of adverse effects. Ideally, these patients should be
included in clinical trials to provide more data for future
analysis and perspectively for better clinical decision
making. For future research, investigators should include
markers in their studies that help to distinguish subsets of
patients e.g. according to risk-profile and HPV association
of the HNSCC to further characterize groups at high risk
for adverse effects and those most likely to benefit.Additional file
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